press release

May 5, 2017

Alnylam to Webcast R&D Day on Thursday, March 6, 2008CAMBRIDGE, Mass. (BUSINESS WIRE) March 3, 2008 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will webcast its R&D Day being held Thursday, March 6, 2008 from 9:00 a.m. to 12:00 p.m. ET at the Sofitel New York Hotel in New York City. Alnylam senior management ...

press release

May 5, 2017

Alnylam Pharmaceuticals Reports First Quarter 2008 Financial ResultsCAMBRIDGE, Mass., May 08, 2008 (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter of 2008, and company highlights. "We have demonstrated significant progress in the first quarter across all dimensions scientific, clinical, and business," said John Maraganore, Ph.D., Chief Executive ...

press release

May 5, 2017

CAMBRIDGE, Mass. (BUSINESS WIRE) Aug. 6, 2008 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter of 2008, and company highlights. "RNAi is now broadly recognized as a transformative breakthrough for the discovery of innovative medicines and Alnylam continues to lead the way across key value drivers of scientific leadership, ...

press release

May 5, 2017

Alnylam Pharmaceuticals Reports Third Quarter 2008 Financial Results Achieves Strongest Quarterly Revenue to Date at $26 Million and Ends Quarter with $520 Million in Cash, Excluding Recent Receipt of $20 Million Milestone Payment Raises Year End Cash Guidance to Greater than $500 Million Advances ALN TTR, an RNAi Therapeutic for the Treatment of TTR Amyloidosis, as New ...

press release

May 5, 2017

Alnylam and Inex Form Strategic Technology Alliance to Discover and Develop RNAi Therapeutics with Lipid Based Delivery FormulationsCAMBRIDGE, Mass. & VANCOUVER, British Columbia (BUSINESS WIRE) Jan. 9, 2007 Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, and Inex Pharmaceuticals Corporation (TSX:IEX) announced today that Alnylam has taken a worldwide exclusive license to Inex's liposomal delivery formulation technology for the discovery, ...

press release

May 5, 2017

Alnylam Announces Key Product and Business Goals for 2007CAMBRIDGE, Mass., Jan 08, 2007 (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today its key product and business goals for 2007, including financial guidance. "The year 2006 was transformational for Alnylam, and for the field of RNAi. We intend to build significantly on this progress in 2007 ...

press release

May 5, 2017

Alnylam Scientist Awarded Two Industry HonorsCAMBRIDGE, Mass. (BUSINESS WIRE) Feb. 28, 2007 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that Dr. Rachel Meyers, Director of Research at Alnylam, has been recognized with two industry honors. She has been named as one of R&D Directions' "Top 20 Most Notable People in R&D," and as one of Mass ...

press release

May 5, 2017

Alnylam Pharmaceuticals Reports Fourth Quarter and 2006 Financial Results Revenues and Cash Position Significantly Strengthened Year Over Year CAMBRIDGE, Mass. (BUSINESS WIRE) Feb. 7, 2007 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the quarter and year ended December 31, 2006, company highlights, and guidance and goals for 2007. "The year 2006 ...

press release

May 5, 2017

Alnylam Pharmaceuticals Reports First Quarter 2007 Financial ResultsCAMBRIDGE, Mass. (BUSINESS WIRE) May 9, 2007 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the quarter ended March 31, 2007 and company highlights. "We have made important advancements already this year, and anticipate continued progress on many fronts in the months to come," said ...

press release

May 5, 2017

Roche and Alnylam Form Major Alliance on RNAi TherapeuticsRoche accesses Nobel Prize winning technology for drug discovery and development Alnylam's site in Germany to become Roche's Center of Excellence for RNAi therapeutics Alnylam to receive 331 million US dollars in upfront payments and equity investment NUTLEY, N.J., July 9 /PRNewswire FirstCall/ Roche and the US based biopharmaceutical company Alnylam Pharmaceuticals, ...